Here's what most people miss about the FDA's uniQure reversal: it signals a broader global shift...

Here's what most people miss about the FDA's uniQure reversal: it signals a broader global shift towards regulatory flexibility for rare disease gene therapies.

This isn't just about one drug; it's a strategic opening. For Indian biopharma, this means exploring R&D in rare diseases with a clearer path to accelerated approval globally. Patient access will drive policy.

https://medcitynews.com/2026/06/uniqure-fda-reversal-huntingtons-gene-therapy-amt-130-regulatory-flexibility-neurodegeneration-qure/